ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
- Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
- Patients who have received any experimental drug within the past four months (prior to
the first dosing day of the study) or who have previously received another CCR5
antagonist.
- Patients with evidence of decompensated liver disease.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Boston, Massachusetts
- Frankfurt,
- Hamburg,
- Koeln,
- London,
- London,
- Montreal, Quebec
- Buenos Aires, Ciudad de Buenos Aires
- Buenos Aires, Ciudad de Buenos Aires
- Buenos Aires, Ciudad de Buenos Aires
- El Palomar, Provincia de Buenos Aires
- Isidro Casanova, Provincia de Buenos Aires
- Rosario, Provincia de Santa Fe
- Buenos Aires,
- Cordoba,
- Sydney, New South Wales
- Sydney, New South Wales
- Sydney, New South Wales
- Sydney, New South Wales
- Bisbane, Queensland
- Brisbane, Queensland
- Nambour, Queensland
- Adelaide, South Australia
- Melbourne, Victoria
- Melbourne, Victoria
- Calgary, Alberta
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Santiago, Santiago RM
- Orleans,
- Frankfurt, Frankfurt am Main
- Berlin,
- Berlin,
- Bonn,
- Cologne,
- Düsseldorf,
- Hannover,
- Dublin,
- Nagoya,
- Guadalajara, Jalisco
- Leon,
- Mexico City,
- Warsaw,
- Badalona, Catalonia
- Barcelona, Catalonia
- Barcelona, Catalonia
- Madrid,
- Madrid,
- Malaga,
- Seville,
- Valencia,
- Bangkok,
- Edinburgh, Lothian
- Brighton, Sussex
- Coventry, Warwickshire
- London,
- London,
- Frankfurt am Main,
- Koeln,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Phase 2 Study Of PF-00232798 In HIV Positive Patients | |||
Official Title ICMJE | A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798 | |||
Brief Summary | To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | HIV | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 43 | |||
Original Enrollment ICMJE | 20 | |||
Actual Study Completion Date ICMJE | September 2008 | |||
Actual Primary Completion Date | September 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00495677 | |||
Other Study ID Numbers ICMJE | A7691009 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | August 2013 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |